Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SCAN domain containing 2 pseudogene (SCAND2P) is a non-protein-coding genomic sequence in humans, classified as a pseudogene[5][1][2]. SCAND2P is predicted to play roles in transcriptional regulation—possibly by acting as a DNA-binding transcription factor or through noncoding RNA mechanisms influencing RNA polymerase II activity[5][3][4]. The SCAN domain is a protein motif characterizing a subfamily of nuclear Krüppel-like zinc finger proteins, though SCAND2P itself does not encode a functional protein[3]. As with some pseudogenes, there is theoretical potential for participation in gene regulation, including possible influence on cancer progression via microRNA decoy or RNA interference pathways, but there is no direct evidence of SCAND2P’s involvement in disease or clinical applications[4][5]. No drugs interact with SCAND2P, and it is not used as a biomarker. Its identification as a therapeutic target is incorrect: pseudogenes are generally not considered direct drug targets[5][3][4].
None applicable. As a pseudogene, SCAND2P is not targeted by drugs via conventional mechanisms
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SCAN domain containing 2 pseudogene (SCAND2P).